“We are the only academic program that supports this research as well as helping patients, trying to advance science. The gastrointestinal tract is a very important part of our body, an active participant in everything else that happens… Microbes that live in the colon participate in all physiological processes, calibrating immune responses, interacting with the nervous system and regulating energy metabolism… [One of our main] objectives is to support early phase academic trials in different indications. You’ll hear from some of the investigators leading those efforts today, briefly. Because the microbes are involved in pretty much every aspect of human physiology, the potential spectrum of indications is extremely broad.”
"Our newest research we’ve done shows that now over 90% of children with autism have high levels of metabolites that are toxic... and come from bacteria in yeast. One example, para-cresol, in 17 studies, every study showing it’s elevated in Autism. We know it’s toxic in many ways. We discovered it’s not just para-cresol but many, many other bacteria and yeast metabolites that have similar effects. What’s exciting is that the only study we know of on how to decrease para-cresol was our first microbiota transplant study showing we were able to decrease it down to normal. We were also able to greatly improve GI symptoms."
A parent of a 14-year-old Autism patient shared, “She’s a totally different kid, her improvement is off the charts. She is off almost all of her prescription medications... She is significantly more flexible, pleasant, balanced and present. I would love to see what her microbiome looks like once you get that data. This is just a miracle and our family couldn’t be more grateful.”
“In this first trial, which is now published in four papers, we showed that FMT was safe in arguably the most immunocompromised, fragile patient population in medicine… FMT modulated the microbiome with effects that … have been shown to be associated with better outcomes, particularly better engraftment seems to protect against acute GVHD. [The]second trial, which we are several months through is that by increasing the dose of FMT and by selecting the best stool donor we might be able to better prevent GVHD.”
“Hidradenitis Suppurativa is a relatively common autoinflammatory skin condition with devastating effects on quality of life and limited treatment options. HS involves skin and gut microbial dysbiosis that may be drivers of [the] disease. Research is underway to evaluate whether Microbiota Transplant Therapy will be an effective therapy for HS. We’ve had a few patients finish treatment and early results are very exciting.”
This video publication is pending filing of Intellectual Property for the clinical trial. Please stay tuned for additional details.
